ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 050,26
1,36%
Dow Jones
41 433,48
0,00%
DAX
22 718,14
1,80%
Brent Oil
70,165
0,65%
Bitcoin
83 054,30
0,25%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Elevation Oncology Inc (ELEV)

  7. Elevation Oncology Inc (ELEV) Actualités

ELEV

Elevation Oncology (ELEV)

Elevation Oncology Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ELEV
DateHeureSourceTitreSymboleSociété
06/03/202523h12Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ELEVElevation Oncology Inc
06/03/202522h52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELEVElevation Oncology Inc
06/03/202522h30PR Newswire (US)Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
25/02/202513h30PR Newswire (US)Elevation Oncology to Participate in Upcoming Investor ConferencesNASDAQ:ELEVElevation Oncology Inc
19/02/202522h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
14/02/202519h34Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ELEVElevation Oncology Inc
13/01/202513h30PR Newswire (US)Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming MilestonesNASDAQ:ELEVElevation Oncology Inc
12/12/202413h30PR Newswire (US)Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid TumorsNASDAQ:ELEVElevation Oncology Inc
05/12/202413h30PR Newswire (US)Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024NASDAQ:ELEVElevation Oncology Inc
26/11/202413h30PR Newswire (US)Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare ConferenceNASDAQ:ELEVElevation Oncology Inc
15/11/202401h05Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ELEVElevation Oncology Inc
06/11/202413h30PR Newswire (US)Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
06/11/202413h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ELEVElevation Oncology Inc
23/09/202413h30PR Newswire (US)Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2NASDAQ:ELEVElevation Oncology Inc
03/09/202413h30PR Newswire (US)Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ELEVElevation Oncology Inc
06/08/202413h10PR Newswire (US)Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
06/08/202413h00PR Newswire (US)Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2NASDAQ:ELEVElevation Oncology Inc
27/06/202413h30PR Newswire (US)Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction CancerNASDAQ:ELEVElevation Oncology Inc
10/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELEVElevation Oncology Inc
09/05/202422h39Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELEVElevation Oncology Inc
07/05/202413h30PR Newswire (US)Elevation Oncology to Present at the Citizens JMP Life Sciences ConferenceNASDAQ:ELEVElevation Oncology Inc
02/05/202413h30PR Newswire (US)Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
08/04/202422h30PR Newswire (US)Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
06/03/202413h30PR Newswire (US)Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business AchievementsNASDAQ:ELEVElevation Oncology Inc
06/03/202413h00Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ELEVElevation Oncology Inc
05/03/202422h50PR Newswire (US)Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:ELEVElevation Oncology Inc
04/03/202422h21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ELEVElevation Oncology Inc
04/03/202413h30PR Newswire (US)Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of DirectorsNASDAQ:ELEVElevation Oncology Inc
22/02/202413h30PR Newswire (US)Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanNASDAQ:ELEVElevation Oncology Inc
14/02/202422h45Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ELEVElevation Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:ELEV

Dernières Valeurs Consultées

EU
SGO
Cie de SaintGobain
EU
BN
Danone
USI
USTECH100
US Tech 100
EU
VK
Vallourec
NYSE
DIS
Walt Disney
EU
BEL20
Bel 20
EU
CS
Axa
EU
HO
Thales
EU
DG
Vinci
COIN
ADAUSD
Cardano
FTSE
UKX
FTSE 100
EU
RNO
Renault
COIN
ETHUSD
Ethereum
NYSE
MCD
McDonalds
NYSE
MRK
Merck
COIN
DOGEUSD
Dogecoin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces